Researchers at the University of Illinois at Urbana-Champaign and at the University of California, San Francisco, have been delving into the mechanisms by which mutations result in elevated expression of the protein called telomerase.
Israel's BioLineRx has unveiled positive preclinical data for its experimental treatment for chronic myeloid leukemia, a progressive blood and bone marrow cancer.
Researchers have found a possible new way to treat cancer by exploiting a biological weakness in the most commonly mutated gene involved in human cancers.
New genes identified by scientists at the University of Louisville in Kentucky may indicate a person's predisposition to excess abdominal fat, which can be an indicator of more serious health conditions, such as cardiovascular disease, Type 2 diabetes and cancer.
Researchers at Vanderbilt University have discovered promising drug targets for previously hard-to-treat kinds of melanoma, suggesting that some cancers believed not to have such targets actually do.
Scientists believe that for the first time, they have linked the gene CUX1 to the development of one in every 100 tumors in cancer patients.
The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
As the genomics community inches closer to realizing the $1,000 genome, Genia Technologies has landed $5.3 million, the largest NIH grant to date under a program to advance genome sequencing technology.
Seattle BioMed has been awarded a $16.6 million grant from the National Institute of Allergy and Infectious Diseases that will allow it to perform what it believes will be the most comprehensive analysis to date of tuberculosis progression from latent infection to active disease.